Pharmacy & Therapeutics - September 2008 - (Page 498)

CONTENTS Cover: Molecular model of an insulin hexamer. See related articles on pages 532, 546, and 550. (© Jean Claude Revy. ISM / Phototake. All rights reserved.) September 2008 FEATURES Effect of Prescription Copays on Adherence and Treatment Failure with Oral Antidiabetic Medications Increased cost sharing by patients results in the reduced use of prescription drugs. A retrospective study by the authors found that diabetic patients did not adhere to their regimens, and thus did not meet target treatment goals, if they were required to pay part of the cost of their medications. John Barron, PharmD; Peter Wahl, MLA, MS; Maxine Fisher, PhD; And Craig Plauschinat, PharmD, MPH HEALTH CARE AND LAW DEPARTMENTS Editorial 503 David Nash, MD, MBA, describes eight emerging technology trends that are transforming markets and businesses and may soon be coming to a P&T committee near you. Medication Errors 504 In part 2 of a two-part article, Matthew Grissinger, RPh, FASCP, explains how P&T committee members can be negatively influenced when they encounter myths and misconceptions about formularies. Prescription: Washington 511 Stephen Barlas discusses how taxpayers might be able to save almost $90 million per year if a bill were passed to eliminate the inflated prices for Part D Medicare benefits. New Drugs/Drug News/ New Medical Devices 513 From Cleviprex to Xenazine, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates. Drug Forecast 523 Dr. Egerton reviews ixabepilone (Ixempra) for metastatic or locally advanced breast cancer. 498 P&T® 532 Vaccine Declinations Present New Challenges for Public Health Immunizations can protect large numbers of people in a community—even those who have not been inoculated. However, the reluctance of growing numbers of people to receive vaccinations for themselves and their children raises the risk of reducing “herd immunity,” which can lead to widespread infection in a population. Robert I. Field, JD, MPH, PhD COMMENTARY 542 Universal Health Care in America Can the Massachusetts Model Work Nationwide? Every citizen 18 years of age and older in Massachusetts is required to obtain health insurance. This article describes the state’s progress and discusses how it might influence proposals for health care reform offered by the two presidential candidates. Miriam Reisman MEETING HIGHLIGHTS 544 Digestive Disease Week and American Diabetes Association Therapies covered include balsalazide (Colazal) and infliximab (Remicade) for ulcerative colitis; infliximab/methotrexate and certolizumab pegol (Cimzia) for Crohn’s disease; and glucose-lowering strategies, as well as a combination of sitagliptin (Januvia) and metformin (Glucophage), for diabetes. Walter Alexander 546 Pharmaceutical Approval Update Topics include clevidipine (Cleviprex) for reducing blood pressure; repaglinide/ metformin (PrandiMet) for improving glycemic control; and difluprednate ophthalmic emulsion (Durezol) for treating inflammation and pain after ocular surgery. Marvin M. Goldenberg, PhD, RPh, MS 550 • September 2008 • Vol. 33 No. 9

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - September 2008

Pharmacy & Therapeutics - September 2008 Contents Editorial Medication Errors Prescription: Washington New Drugs/Drug News/New Medical Devices Drug Forecast Effect of Prescription Copays on Adherence and Treatment Failure with Oral Antidiabetic Medications Vaccine Declinations Present New Challenges for Public Health Universal Health Care in America Digestive Disease Week and American Diabetes Association Pharmaceutical Approval Update

Pharmacy & Therapeutics - September 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.